Bank of New York Mellon
ATRA icon

Bank of New York Mellon’s Atara Biotherapeutics ATRA Stock Holding History

Bank of New York Mellon’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,101
Closed -$245K – 4131
2024
Q1 		$245K Sell
14,101
-1,689
-11% -$30K ﹤0.01% 3869
2023
Q4 		$202K Buy
15,790
+2,376
+18% +$55.4K ﹤0.01% 3948
2023
Q3 		$496K Sell
13,414
-164
-1% -$7.3K ﹤0.01% 3546
2023
Q2 		$547K Buy
13,578
+555
+4% +$31.4K ﹤0.01% 3538
2023
Q1 		$944K Buy
13,023
+243
+2% +$23.6K ﹤0.01% 3155
2022
Q4 		$1.05M Sell
12,780
-12,906
-50% -$1.34M ﹤0.01% 3176
2022
Q3 		$2.43M Buy
25,686
+13,890
+118% +$1.56M ﹤0.01% 2722
2022
Q2 		$2.3M Sell
11,796
-815
-6% -$133K ﹤0.01% 2755
2022
Q1 		$2.93M Buy
12,611
+239
+2% +$76.1K ﹤0.01% 2718
2021
Q4 		$4.88M Buy
12,372
+251
+2% +$106K ﹤0.01% 2478
2021
Q3 		$5.42M Buy
12,121
+1,039
+9% +$372K ﹤0.01% 2445
2021
Q2 		$4.31M Sell
11,082
-762
-6% -$272K ﹤0.01% 2562
2021
Q1 		$4.25M Sell
11,844
-381
-3% -$168K ﹤0.01% 2511
2020
Q4 		$6M Buy
12,225
+1,188
+11% +$548K ﹤0.01% 2275
2020
Q3 		$3.58M Buy
11,037
+1,184
+12% +$403K ﹤0.01% 2390
2020
Q2 		$3.59M Buy
9,853
+1,145
+13% +$289K ﹤0.01% 2369
2020
Q1 		$1.85M Buy
8,708
+236
+3% +$74.9K ﹤0.01% 2586
2019
Q4 		$3.49M Sell
8,472
-336
-4% -$116K ﹤0.01% 2523
2019
Q3 		$3.11M Buy
8,808
+1,070
+14% +$399K ﹤0.01% 2516
2019
Q2 		$3.89M Buy
7,738
+357
+5% +$252K ﹤0.01% 2456
2019
Q1 		$7.33M Sell
7,381
-46
-0.6% -$42.7K ﹤0.01% 2136
2018
Q4 		$6.45M Buy
7,427
+247
+3% +$229K ﹤0.01% 2147
2018
Q3 		$7.42M Buy
7,180
+34
+0.5% +$33.2K ﹤0.01% 2198
2018
Q2 		$6.57M Buy
7,146
+259
+4% +$278K ﹤0.01% 2242
2018
Q1 		$6.71M Buy
6,887
+1,718
+33% +$1.57M ﹤0.01% 2193
2017
Q4 		$2.34M Buy
5,169
+216
+4% +$79.8K ﹤0.01% 2754
2017
Q3 		$2.05M Sell
4,953
-76
-2% -$28.6K ﹤0.01% 2822
2017
Q2 		$1.76M Buy
5,029
+225
+5% +$86.7K ﹤0.01% 2922
2017
Q1 		$2.47M Buy
4,804
+243
+5% +$101K ﹤0.01% 2720
2016
Q4 		$1.62M Buy
4,561
+775
+20% +$328K ﹤0.01% 2977
2016
Q3 		$2.02M Sell
3,786
-199
-5% -$108K ﹤0.01% 2754
2016
Q2 		$2.24M Buy
3,985
+688
+21% +$330K ﹤0.01% 2646
2016
Q1 		$1.57M Sell
3,297
-200
-6% -$90K ﹤0.01% 2804
2015
Q4 		$2.31M Sell
3,497
-29
-0.8% -$21.9K ﹤0.01% 2631
2015
Q3 		$2.77M Buy
3,526
+484
+16% +$590K ﹤0.01% 2544
2015
Q2 		$4.01M Buy
3,042
+1,843
+154% +$2.11M ﹤0.01% 2500
2015
Q1 		$1.25M Buy
1,199
+401
+50% +$265K ﹤0.01% 3171
2014
Q4 		$534K Buy
+798
New +$487K ﹤0.01% 3595

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bank of New York Mellon's ATRA Position: Q2 2024 in Review

Bank of New York Mellon sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 14,101 shares — an estimated $245K sold.

Bank of New York Mellon first reported a position in ATRA in Q4 2014 and held it in 38 quarters. The position peaked at $7.42M in Q3 2018. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Bank of New York Mellon reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 14,101 Atara Biotherapeutics shares in Q2 2024, an estimated $245K.
  • Bank of New York Mellon first reported a position in Atara Biotherapeutics in Q4 2014 and held it in 38 quarters.
  • Bank of New York Mellon's Atara Biotherapeutics position peaked at $7.42M in Q3 2018.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.